Pharma Exec Collapses During White House Event on Drug Prices

"Live TV coverage of the event shows Novo Nordisk executive Gordon Findlay slumping to the floor inside the Oval Office, with several men nearby helping to guide his body safely to the ground. Medicare and Medicaid administrator Mehmet Oz grabbed Findlay under the shoulders to help him to the ground. Trump stands up from behind his desk in the Oval Office, but doesn't intervene. Health secretary Robert Kennedy Jr. can be seen walking briskly away from Findlay."

""During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted," White House Press Secretary Karoline Leavitt said in a statement. "The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly." The event was announcing a deal in which drug makers Eli Lilly and Novo Nordisk would significantly bring down the prices of Glucagon-like peptide-1 receptor agonists, or GLP-1 agonists."

"According to recent Gallup data, obesity rates in the United States fell back down to 37 percent this year, from hitting a peak of 39.9 percent in 2022. It's unclear how much of this change can be attributed to the widespread adoption of GLP-1 agonist medications; however, it likely played a significant role. Despite their effectiveness, the drugs have proven prohibitively expensive for many Ame"

Novo Nordisk executive Gordon Findlay fainted inside the Oval Office during a White House announcement to lower obesity drug costs. Several men, including Medicare and Medicaid administrator Mehmet Oz, helped guide Findlay to the ground while President Donald Trump did not intervene and Health Secretary Robert F. Kennedy Jr. walked away; press were asked to leave. The White House Press Secretary said the medical unit responded and the man was okay. The announcement described a deal in which Eli Lilly and Novo Nordisk would significantly reduce prices of GLP-1 receptor agonists, sold as Wegovy and Zepbound. Gallup data show U.S. obesity rates fell to 37 percent from 39.9 percent in 2022, and the drugs, though effective, remain prohibitively expensive for many people.

Read at Futurism